Insmed Q3 Revenue Jumps 268% to $524M as BRINSUPRI Hits $398M in US Sales
INSM is trading near its 52-week low of $90.39 (9.3% above the low).
Summary
Insmed's Q3 revenue reached $524.4 million, up 268%, on $398.1 million of US BRINSUPRI sales, while the net loss narrowed to $100.3 million. The filing also confirms the CFO departure effective October 30, 2026 and names interim finance leads.
Key Events · Earnings and Guidance · INSM
-
Q3 Revenue Up 268% to $524.4M
Product revenues, net were $524.4 million versus $142.3 million in Q3 2025, driven by $398.1 million of US BRINSUPRI sales and $124.4 million of ARIKAYCE.
-
Net Loss Narrows to $100.3M
Quarterly net loss was $100.3 million, or $0.46 per share, versus $370.0 million, or $1.75 per share, a year earlier; nine-month net loss was $277.1 million.
-
Cash Burn Falls; $1.1B Liquidity
Nine-month operating cash use was $348.0 million versus $687.4 million in 2025, leaving $396.6 million of cash and $750.1 million of marketable securities at September 30, 2026.
-
AstraZeneca $35M Milestone Triggered
The $1.0 billion annual BRINSUPRI net sales milestone was deemed probable, creating a $35.0 million payable and intangible asset on top of the $15.0 million Japan approval milestone.
Analysis · INSM · Life Sciences
The BRINSUPRI launch is now converting into real scale: product revenue reached $524.4 million, up from $142.3 million a year ago, with $398.1 million of that from US BRINSUPRI sales. Quarterly net loss narrowed to $100.3 million (-$0.46 per share) from $370.0 million (-$1.75), and nine-month operating cash burn fell to $348.0 million from $687.4 million. Spending, however, is climbing fast — R&D rose 45% to $270.0 million and SG&A 36% to $253.0 million, both tied to TPIP and the BRINSUPRI commercial build. The balance sheet holds $396.6 million of cash plus $750.1 million of marketable securities, which management says funds at least the next 12 months. The filing also confirms the CFO handoff: Sara Bonstein leaves October 30, 2026, with CEO William Lewis as interim principal financial officer and Patrick Kane as interim principal accounting officer.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INSM was trading at $98.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2B. The 52-week trading range was $90.39 to $212.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.